Compare Adaptive Biotechnologies Corp (ADPT) vs Abercrombie & Fitch Co. (ANF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Abercrombie & Fitch Co. — how do they compare? Adaptive Biotechnologies Corp trades at $25.41 (market cap $4.04B), while Abercrombie & Fitch Co. trades at $113.05 (market cap $5.24B). The key difference: Abercrombie & Fitch Co. is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Abercrombie & Fitch Co. nearer its low. Which is the better fit depends on your goals.
| ADPT | ANF | |
|---|---|---|
Market Cap | $4.04B | $5.24B |
Sector | Health | Consumer Cyclical |
52-Week High | $25.45 | $129.85 |
52-Week Low | $12.30 | $65.61 |
Enterprise Value | $4.10B | $5.91B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.
The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.
ANF trades at $113.06, down 4.61% on the day, but maintains strong fundamentals with a P/E of 11.41 and robust profitability margins. The stock exhibits a bullish technical trend with moving averages supporting upside, though oscillators signal overbought conditions. Recent earnings beats and a return to positive cash flow in 2026 highlight operational strength, while institutional interest grows, as seen with Amundi's increased stake in Q2 2026.
Outlook remains positive driven by earnings momentum and valuation appeal, but risks include Hollister brand headwinds and geopolitical tensions affecting EMEA growth. Analyst consensus leans bullish with a $112.86 price target, suggesting limited upside from current levels amid near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Abercrombie & Fitch Co.
Abercrombie & Fitch Co is a specialty retailer that sells casual clothing, personal-care products, and accessories for men, women, and children. It sells direct to consumer through its stores and websites, which include the Abercrombie & Fitch, Abercrombie kids, and Hollister brands. Most stores are in the United States, but the company does have many stores in Canada, Europe, and Asia. All stores are leased. Abercrombie ships to well over 100 countries via its websites. The company sources its merchandise from dozens of vendors that are primarily located in Asia and Central America. Abercrombie has two distribution centers in Ohio to support its North American operations. It uses third-party distributors for sales in Europe and Asia.
Read more on ANF →
